4th Mitochondrial Dysfunction Drug Development Summit

In light of Anavex's announcement of its first entire clinical gene pathway data in patients with Rett syndrome, coupled with Mission Therapeutics' recent fundraising of £25.2 million to progress the clinical development of its lead drug candidates, there has been increasing evidence of interest taking place towards broader disease groups with underlying pathogenesis from mitochondrial dysfunction.

This November, we will unite 60+ C-Level, Biologist, Preclinical, Translational, and Innovation-Scouting Leaders who are building on from the industry's latest setbacks to innovate mitochondrial-targeting approaches and expand novel therapeutic opportunities. From cutting-edge research backed by academia to transformative pipeline updates from preclinical and clinical settings revealed by the industry, this is your chance to get involved and de-risk clinical development by discovering and validating biomarkers for defined endpoints.

URLs:
Website: https://go.evvnt.com/2562504-0?pid=10018
Brochure: https://go.evvnt.com/2562504-2?pid=10018
Tickets: https://go.evvnt.com/2562504-3?pid=10018

Prices:
Drug Developer Pricing - Conference + Workshop Day: USD 3497.00,
Drug Developer Pricing - Conference Only: USD 2599.00,
Not-for-Profit, Academic, Start-Up Pricing - Conference + Workshop Day: USD 2897.00,
Not-for-Profit, Academic, Start-Up Pricing - Conference Only: USD 2199.00,
Service Provider Pricing - Conference + Workshop Day: USD 4297.00,
Service Provider Pricing - Conference Only: USD 3199.00

Speakers: Amy Chadwick, Professor, University of Liverpool, Baerbel Rohrer, Chief Executive Officer, MitoChem Therapeutics, Baruch Harris, Chief Operating Officer, Pretzel Therapeutics, Brad Hubbard, Assistant Professor, University of Kentucky, Christopher Missling, President and Chief Executive Officer, Anavex, Cynthia Arbeeny, Chief Scientific Officer, Mitotherapeutix, Dima Martini-Drew, Global Early Stage Medical Affairs Lead, Astellas Pharma, Enchi Liu, Senior Vice President of Translational Sciences, Tranquis Therapeutics Inc., Jack Howden, Senior Scientist, MSD, John Geisler, Chief Scientific Officer, Mitochon Pharmaceuticals, Karin Westlund, Professor, University of New Mexico Health Sciences Center, Kira Mann, Chief Executive Officer, MitoAction, Krista Casazza, Scientific Director, PATH, Lan Wei-LaPierre, Assistant Professor, University of Florida, Michal Minczuk, Cancer Research UK, Senior Representative, Agilent Technologies, Sophia Zilber, Board Member, Cure Mito foundation, Tom Benson, Chief Executive Officer, Mitrix Bio